Written By: Robert King, Esq.
Legal Review By: Daniel Nigh, Esq.
The Ozempic Lawsuit is an active lawsuit
See If You Qualify

Individuals are filing Ozempic lawsuits, claiming that the drug, semaglutide, can lead to severe gastroparesis, ileus, intestinal blockages, and other gastrointestinal issues. The lawsuits allege that the manufacturer, Novo Nordisk, failed to adequately warn patients of these side effects. The first lawsuit was filed on August 2, 2023, and the number of cases continues to grow.

Ozempic Lawsuit Overview

Ozempic is semaglutide approved by the U.S. Food and Drug Administration (FDA) to help treat patients with type 2 diabetes by helping the pancreas produce more insulin lowering blood sugar. It is also used to reduce the risk of cardiovascular programs. A well-publicized side effect of the weekly injection is that it may help people lose weight.

With increased use of the drug, concern has risen that prolonged use may lead to serious gastrointestinal injuries. Our firm is currently investigating Ozempic lawsuits involving a diagnosis of:

  • Stomach Paralysis / Gastroparesis
  • Bowel Blockage / Ileus
  • Blindness (NAION) / Vision Problems
  • Bile Duct Cancer
  • Lou Gehrig’s Disease (ALS)
  • Gallbladder Cancer
  • Sinus Cancer

If you have been diagnosed with any of the above conditions, or have experienced severe and prolonged vomiting, please contact us right away for a free Ozempic lawsuit evaluation.

Ozempic Lawsuit 2024 Update

July 9, 2024: New Study Links Semaglutide to Increased Risk of Vision Problems

A new study by Dr. Jimena Hathaway, MD, MPH, published in the Journal of the American Medical Association, indicates that Semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, shows an increased risk of vision loss. The study found that in a pool of 16,827 patients, Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) increased more than four times for people taking semaglutide compared to those who took another drug. The analysis was conducted from 2017 to 2023. This is a critical study in the Ozempic lawsuit because the label does not warn of this side effect. Eye doctors and lawyers have suspected vision problems for some time. We expect that the federal court lawsuit will soon include Ozempic vision loss cases, including blindness and blurred vision.

June 28, 2024: Study Reveals Potential Bone Density Reduction with GLP-1 Treatment

In a recent study, Simon Jensen, Ph.D., and others found that GLP-1 treatment, without exercise, could lead to reduced bone density. The study was published on June 25, 2024, in JAMA Network. The most common GLP-1 is Ozempic. The study follows speculation that the reduction in nutrient and water absorption by the body could have long-term health implications. So far, the Ozempic lawsuit has focused on gastrointestinal side effects like gastroparesis and bowel obstructions.

June 17, 2024: Ozempic Lawsuit Progresses with New Judicial Orders and Status Conference

The Ozempic lawsuit is again beginning to move. The first status conference with the new judge was held on June 10, 2024. The focus was on the logistics of moving the MDL forward. Since the conference, the judge has issued two mundane orders. First, lawyers who wish to file cases into the GLP-1 MDL will not have to pay a fee to be admitted pro hac vice. Second, the parties have filed a motion, seemingly with permission from the judge, in regards to privilege logs. Parties in lawsuits have to turn over relevant information to the other side in lawsuits like this one. However, sometimes there are privileges that can be asserted. If a document is not turned over due to privilege (like a communication with a lawyer), then the document is supposed to be logged and the other side informed that it exists. This log is called a privilege log and is part of every case.

June 8, 2024: New Judge Appointed in Ozempic Lawsuit, Case Moves Forward

There is a new judge in the Ozempic Lawsuit. Case Management Order number 7 was filed on June 6, 2024, by Judge Karen Spencer Marston. Judge Marston will be the new judge overseeing the case. She was nominated for the federal bench following a lengthy career as an Assistant US Attorney. The next conference will be held in person in the Eastern District of Pennsylvania on June 10, 2024.

June 2, 2024: Ozempic Lawsuit Paused in Federal Court Awaiting New Judge Appointment

The Ozempic lawsuit pending in federal court is at a standstill until a new judge is appointed following the unexpected death of the previous judge. We also expect to see cases continue to be filed in New Jersey state court. Federal court is the appropriate venue when there are parties from two different states. Cases that will be brought against Novo Nordisk by residents of the State of New Jersey will probably have to be brought in New Jersey court. It is possible that other plaintiffs will file claims in New Jersey state court as well.

May 2024

May 22, 2024: Science Day Canceled in Ozempic Lawsuit, Case Reassignment Possible

Science Day has been canceled in the Ozempic Lawsuit. The Chief Judge of the Eastern District of Pennsylvania, Mitchell Goldberg, issued an order on May 21, 2024, vacating Case Management Order number 5 and canceling Science Day. The case must be reassigned. Perhaps Judge Goldberg will be the new judge on the case.

May 20, 2024: Judicial Shift in Ozempic Lawsuit After Judge Pratter’s Passing Impacts Proceedings

The Ozempic lawsuit is in a period of flux with the death of Judge Pratter. Judge Pratter was the presiding Judge in the lawsuit and was taking an active and aggressive role. The plaintiffs and defendants will now await a new judge to be appointed by the Judicial Panel on Multidistrict litigation. Plaintiffs will hope for a more liberal plaintiff friendly judge. The Eastern District of Pennsylvania is thought to be pro plaintiff, with several large verdicts in Philadelphia recently. The death of Judge Pratter may delay the case temporarily.

May 19, 2024: Novo Nordisk and Eli Lilly Outline Legal Strategy to Reduce Liability and Challenge Plaintiff Claims on Ozempic and Mounjaro

Novo Nordisk and Eli Lilly recently outlined their strategy in a defendant statement to reduce liability and minimize plaintiff recoveries. Both companies covered the benefits and advantages of Ozempic and Mounjaro and countered the plaintiffs’ focus on failure to warn for GLP-1RAs. The defense categorized the lawsuits into different injury classes which puts pressure on the plaintiffs to provide specific evidence for each of the cases. They’re also pushing for plaintiffs to disclose information about unfiled cases, but that is not legally required. They also pushed for early motions to dismiss by requesting objective testing for “gastroparesis,” which can complicate the plaintiffs’ burden of proof.

May 3, 2024: Plaintiffs Respond to Defendants’ Position Statement in Ozempic Lawsuit

The plaintiffs filed a statement in the Ozempic lawsuit responding to the defendants’ “Statement of the Case”. The plaintiffs’ statement outlines the framework they will argue and attempts to dismiss the defendants’ arguments from their filing. The statement highlights a conflict between the two parties about what should be required to file a lawsuit. The defendant has argued that a plaintiff should be required to have a gastric emptying study to bring a lawsuit. The plaintiffs’ lawyers say that the test is not required. Instead, they assert that a doctor’s diagnosis of gastroparesis, stomach paralysis, or bowel injuries is sufficient, at least for the early stages of a lawsuit.

April 2024

April 30, 2024: ‘Science Day’ Scheduled for the Ozempic Lawsuit

Judge Pratter issued Case Management Order number 5 in the Ozempic lawsuit and scheduled “Science Day” for June 14, 2024. Science Day will provide an overview of the medical and scientific issues relevant to the case. Plaintiffs and Defendants will have a designated time slot to present their positions to the Judge during Science Day. It would be interesting to know whether the plaintiffs’ lawyers will focus on Ozempic and other semaglutide drugs or split their time with some of the Eli Lilly drugs as well. Unfortunately, the Judge ruled that the record from Science Day will be confidential to the Court.

April 21, 2024: Drawing Parallels – Ozempic Lawsuit and Benicar MDL Settlement Analysis

Some guidance in the Ozempic lawsuit might be gained from a review of the Benicar MDL. Benicar was a common blood pressure medication in the early 2000s. Like the Ozempic case, the Benicar case alleged a failure to warn of serious gastrointestinal side effects, like chronic diarrhea and bowel obstructions. In 2017, the case settled for a reported $300 million to 2,300 plaintiffs. Other reports indicated the actual settlement value was closer to $360 million. The most serious cases are reported to have settled for over $500,000, while others received much less. The average, however, seems to have been well over $100,000. It would not surprise us if the settlement matrix in that case is a target for the lawyers in the Ozempic case.

April 20, 2024: Ozempic Lawsuit Is About Whether Users Knew of Potential Side Effects

The plaintiffs and defense have begun to submit their respective positions to the judge in the Ozempic lawsuit. Early court documents show that this case will be about whether the manufacturer properly warned of the side effects. Plaintiff lawyers say that gastroparesis and other bowel injuries are unwarned consequences of the use of Ozempic and similar drugs. The defense states that intestinal issues, some severe, are side effects that everyone knew about. Part of their defense is that the doctors knew of the side effects and had an obligation to inform the patients.

April 11, 2024: Ozempic Lawsuit Joint Defense Statement Filed by Novo Nordisk and Eli Lilly

Defendants Novo Nordisk and Eli Lilly have submitted a joint statement of the case in the ongoing Ozempic lawsuit. This document, filed in federal court on April 9, 2024, aims to outline the defense’s strategy over the coming months. At the time of filing, 117 plaintiffs had initiated lawsuits: 100 cases targeted Novo Nordisk, 8 targeted Eli Lilly, and 9 involved both defendants. According to the defense, GLP-1RA drugs are revolutionary medications with FDA-approved warnings, asserting that they are generally safe and have undergone extensive testing. The defense also claims to have insufficient information about both filed and potential cases. They note a rise in counterfeit products and assert that many plaintiffs alleging “gastroparesis” lack substantial evidence of their diagnosis. This filing provides a significant insight into the defenses planned for the Ozempic lawsuit.

April 10, 2024: Additional Cases Transferred to Eastern District of Pennsylvania

The April 4, 2024, conditional transfer order signed by Tiffaney D. Pete, Clerk of the Panel on Multidistrict Litigation, states that two additional cases were transferred to the United States District Court for the Eastern District of Pennsylvania and have been assigned to Judge Gene Pratter as part of the Ozempic Lawsuit (MDL No. 3094). The Order notes that 17 cases were transferred in the original transfer order on February 2, 2024. Since that time, 36 more cases have been added to the lawsuit. Like most MDLs, the filings have been slow to start with. Most law firms will wait for the lawyers to agree on a short-form complaint, then file their cases. A short-form complaint is a simplified pleading that gives the basics of each plaintiff’s complaint. We expect that the Ozempic complaint will include things like which drug was prescribed to the plaintiff, date of prescription, the diagnosed injury, the theory of liability against, and whether the claim is against Novo Nordisk or Eli Lilly.

April 1, 2024: Ozempic Manufacturer Novo Nordisk Sues Pharmacies for Knock-Offs

Ozempic manufacturer Novo Nordisk continues to pursue lawsuits against pharmacies that sell compounded semaglutide. The FDA has discouraged the National Association of Boards of Pharmacy from compounding Ozempic, Wegovy, and Rybelsus. The FDA further notes that different forms of semaglutide appear to violate federal law. On January 10, 2024, the FDA issued guidance acknowledging the risk and popularity of knock-off Ozempic. The biggest concern is “compounded” Ozempic. Novo Nordisk has settled several lawsuits against pharmacies providing substances that are not, in fact, Ozempic. Of course, the federal lawsuit alleges that even in its purest form, Ozempic can be dangerous, and the manufacturer is now properly warning of the risks associated with the drug.

March 2024

March 23, 2024: Ozempic Lawsuit Leadership Structure Proposed

Plaintiff lawyers in the Ozempic lawsuit have submitted a motion for leadership structure to the court. This is no surprise. Court leadership needs to get to work on setting schedules and making requests for documents from the drug manufacturers Novo Nordisk and Lilly, formerly known as Eli Lilly. Our litigation partner Daniel Nigh, Esq. is a proposed member of the executive committee. Daniel is an experienced dangerous drug lawyer and we expect him to be on the front lines of the litigation of the serious scientific issues in the Ozempic case. We expect the motion to be granted in short order by Judge Pratter.

March 21, 2024: Anticipating a Surge of Ozempic Lawsuits in New Jersey Courts

The Ozempic lawsuit will soon become the Ozempic lawsuits. We believe that a substantial number of Ozempic lawsuits will be filed in New Jersey state court, in addition to the cases being filed in federal court. We expect that law firms with a large volume of Ozempic cases will file some in state court as a way to hedge their bets against putting all their cases into one litigation, in front of one judge. The biggest risk in a large federal court tort case is a bad Daubert ruling. “Daubert” refers to a landmark case that sets the standard for what an expert can testify to. A bad Daubert ruling can lead to the dismissal of all cases. New Jersey is the most likely state court venue because it is the U.S. headquarters of Novo Nordisk, the Ozempic manufacturer. In addition, some lawyers who are not satisfied with their role in the federal court case may choose to file in state court instead. Several Ozempic cases have already been filed in New Jersey state court.

March 20, 2024: Status Conference Update in Ozempic Lawsuit

The first status conference was held in the Ozempic Lawsuit last Thursday. The conference began with the Judge asking for proposals about how the plaintiffs would organize the several lawyers from law firms around the country who are filing cases. Lawyers from Eli Lilly made an aggressive early play asking the judge when they could file for summary judgement. The court said that would be a long time down the road. Early estimates are that Eli Lilly will defend about 10 percent of the cases for their drug, Mounjaro. Some lawyers believe that the most serious injuries come from Ozempic and Wegovy. The comments seem to indicate that the case will include both manufacturers for the foreseeable future. Finally, the court indicated a “science day” where each side gets to present to the Judge about the science involved in this case. Science days help the Judge understand the case more fully as they rule on legal issues. We anticipate science day will occur in the next three months in the Ozempic Lawsuit.


Judge Gene E.K. Pratter, the presiding Judge in the Ozempic lawsuit, will soon appoint lawyers to certain roles and set a discovery schedule. She will also make decisions about what cases are included in the lawsuit and what evidence is allowed to be used at trial. Judge Pratter might be considered a blue-blood judge. She graduated from Stanford and received her law degree from the University of Pennsylvania. The University of Pennsylvania law school is currently ranked #4 in the United States. She was a partner in the law firm of Duane Morris from 1975, until her nomination to the federal bench by George W. Bush. She was confirmed by the Senate on June 15, 2004. She is a member of the adjunct faculty at the University of Pennsylvania. Her resume is that of an experienced and intelligent judge. We expect the Ozempic lawsuit to be one of the largest and most complex in the history of the United States. It is no mistake that the case was assigned to Judge Pratter. Local attorneys know her as a no-nonsense type. We expect Judge Pratter to be impressive this week at her first status conference in the Ozempic litigation and show the lawyers that she is going to run a tight ship.

March 2, 2024: Upcoming Ozempic Lawsuit News

There hasn’t been much news in the Ozempic lawsuit since it became official and was consolidated in the Eastern District of PA. We’ll get our initial look at how the Ozempic lawsuit is shaping up at the first status conference scheduled with judge Gene E.K. Pratter on March 14, 2024. We continue to see Ozempic everywhere on TV and social media. You can’t go very long without being fed its so-called greatness on mainstream news or the countless influencers on Facebook, Instagram, and others. While it is portrayed as a miracle weight loss drug, there is the dark side of it’s serious side effects like stomach paralysis affecting thousands of people.

February 2024

February 28, 2024: Behind the scenes of the Ozempic Lawsuit

The Ozempic lawsuit is in the critical early stages of the Multidistrict Litigation. The politics of mass tort litigation is difficult to understand. Simply put, there are different factions in almost every case. Law firms want power and authority to control the decisions in the case because they have a lot of resources invested in getting the case to become an actual lawsuit. The Ozempic lawsuit highlights the differences between some of the “old guard” lawyers and some of the big firms that are entering mass torts. One big firm filed for consolidation of the Ozempic lawsuit, allegedly without much warning to other law firms. Other lawyers then were forced to rush to get cases filed and have the right to be heard at the JPML hearing. The responding lawyers asked for the case to be transferred to Philadelphia – and the panel granted their request. There is some inherent conflict between law firms and at this point we will see if the different factions can work together to propose a group of lawyers to drive the case forward for the next several years. The judge will appoint a lead counsel and plaintiffs leadership committee in the next several months. The group will then proceed with discovery and learn how Novo Nordisk developed Ozempic, Wegovy, and Rybelsus – and most importantly what they knew about the risks when they failed to warn of stomach paralysis and intestinal blockage.

February 24, 2024: Ozempic manufacturer files lawsuits targeting knockoffs

Ozempic Manufacturer Novo Nordisk is not only being sued in federal and state courts for injuries caused by semaglutide, the official name of the drug contained in Ozempic, Wegovy and Rybelsus they are filing their own lawsuits too. Novo Nordisk owns the patent for semaglutide and no other manufacturer is allowed to produce it. The company has filed at least 12 lawsuits against entities they say are selling knockoff Ozempic. Novo Nordisk has aggressively targeted pharmacies and online drug sellers for “compounding.” Novo Nordisk maintains that they are the only company allowed to sell semaglutide and allege that they do not know what is contained in the compounded drugs being sold online. The company states the compounded drugs are not FDA approved.

February 23, 2024: Ozempic Manufacturer Has faced many lawsuits

Ozempic manufacturer Novo Nordisk is no stranger to lawsuits. The company has recently been in the news because Ozempic lawsuits are popping up everywhere. Earlier this month the federal court cases were centralized in Philadelphia for efficiency. A new case filed in New Jersey State Court, Tinsley v. Novo Nordisk, also suggests that some lawyers think it will be advantageous to stay outside the class action style lawsuit and proceed with a New Jersey state court Ozempic case. It is worth noting that the New Jersey case is a gallbladder case and we believe gallbladder cases will not be part of the federal court lawsuit.

It should be noted that the United States Department of Justice filed a lawsuit against Novo Nordisk nearly 15 years ago for fraudulently and aggressively marketing their diabetes drugs. Novo Nordisk Settled that case brought by Loretta Lynch, United States Attorney for the Eastern District of New York. In 2017 the State of California settled with the Ozempic manufacturer for promoting a type two diabetes drug outside of what it was approved to be used for. In that case the company targeted children for the diabetes drug, even though the FDA had not approved the drug for use in children. Similarly, the current lawsuit alleges that Novo Nordisk aggressively marketed Ozempic using inappropriate tactics and has promoted a diabetes drug for a use inconsistent with FDA approval.

February 21, 2024: Ozempic Manufacturer Failed to Warn of health risks

The Ozempic lawsuit will be largely focused on what the manufacturer knew about the side effects of using Ozempic, and when. Plaintiffs’ lawyers have brought the lawsuit so they will have the burden to prove that Novo Nordisk did something wrong. The most likely claim to be successful is a failure to warn of the dangers associated with the drug. Many lawsuits have been filed alleging that Ozempic the manufacturer knew of the risk of gastroparesis, ileus and bowel obstruction. The allegations also include aggressive and deceptive marketing. On October 5, 2023, an important study, published in JAMA and authored by Mohit Sodhi indicated increased risk of gastroparesis, bowel obstruction and pancreatitis for those using GLP-1 agonists. Ozempic is the trade name for semaglutide. The study used a cohort of over 5,000 randomly selected individuals from the Pharmetrics Plus for Academics Database of over 16 million prescription drug users in the United States. The Ozempic lawsuits began being filed around the United States shortly after this study. By December an application was made to consolidate all Ozempic lawsuits in a federal class action type, Multi-District Litigation. The application was granted, and we are in the early stages of the Ozempic MDL, centered in Philadelphia. The first status conference before the Judge is forthcoming. The first milestones in the case will be selecting lead counsel, filing a master complaint and establishing a preliminary discovery schedule for document production.

February 16, 2024: First Status Conference set in Ozempic lawsuit.

Just a week after the Judicial Panel on Multidistrict litigation created MDL 3094 (the official Ozempic Lawsuit) and transferred all cases to the Eastern District of Pennsylvania, the Hon. Gene E.K. Pratter has scheduled the first status conference for Thursday March 14, 2024. Among the topics to be discussed are: Organization and Process for selecting plaintiff’s lead counsel, scheduling and frequency of future status conferences, filing procedures for motions, responses, complaints, and other documents, and the creation of plaintiff fact sheets. Perhaps the most important agenda item is discussion on whether to keep this just an Ozempic case, or to include other manufactures such as Rybelsis, Wegovy, Trulicity, and Mounjaro.

February 15, 2024: Ozempic Lawsuit Injuries Coming Into Focus

With the Ozempic lawsuit just weeks old, we are refining which injuries will likely be strong cases. It is important to understand that the basis of the lawsuit is the failure to warn about the potential for serious side effects caused using Ozempic and similar drugs. There is solid support for gastroparesis, stomach paralysis, gastrointestinal obstruction, and ileus (bowel obstruction).

With respect to gallbladder cases, most people with these issues will not be eligible in the federal MDL lawsuit. This is because Novo Nordisk, the maker of Ozempic, added a gallbladder warning in March of 2022. This effectively disqualifies anyone with gallbladder complications who took the drug after March 2022. It could also disqualify anyone who took the drug prior to the date of the warning because most states have a two-year statute of limitations to file a lawsuit.

February 4, 2024: Ozempic Lawsuit becomes official

There is now an active Ozempic Multidistrict Litigation, as we expected. This is similar to an Ozempic Class Action Lawsuit. The case will be known as MDL 3094 IN RE: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION. The case will be heard in the Eastern District of Pennsylvania federal court. Hon. Gene E. K. Pratter will be the Judge. This venue is generally considered a plaintiff friendly venue. There have recently been large verdicts in the Philadelphia area against Monsanto in the Roundup litigation. The other big question that was left open during the January 25th hearing was who would be included in the case. Eli Lilly, the manufacturer of Mounjaro, has been included in the Ozempic federal court lawsuit. Eli Lilly has done their best to distance themselves from Novo Nordisk. The Judicial Panel on Multidistrict Litigation (JPML) seems to have been conflicted on whether or not to include them. The order specifically states that if Judge Pratter decides it is not a good decision he has options to separate the defendants. For now, however, Mounjaro is part of the Ozempic lawsuit. The first important question for Judge Pratter will be, who is going to lead this litigation for the plaintiffs’ side.

February 1, 2024: Decision on the Future of Ozempic Lawsuit Looms

The Judicial Panel on Multi-District Litigation is set to rule on how the Ozempic Lawsuit will proceed. At hand remains the question as to the whether the lawsuit will move forward to include only the Ozempic brand itself, which is manufactured by Novo Nordisk, or if other similar drugs such as Ely Lilly’s Mounjaro will become part of the suit. A decision from the JPML is expected in February.

January 2024

January 25, 2024: Pivotal Day For Ozempic Lawsuit

The Ozempic lawsuit is at a critical stage today. The Judicial Panel on Multidistrict Litigation will hear arguments in Santa Barbara, CA, with respect to the application brought by plaintiffs to create a multidistrict litigation. It is nearly certain that they will grant the application because the Ozempic manufacturer does not object. There are two questions remaining, however. First, will drug manufacturer Ely Lilly be included in this case. They make the drug Mounjaro, which is similar, but different from Ozempic. Some lawyers think it is better to keep them separate. Finally, where will the case be located? The application requested the Western District of Louisiana. There are also applications for the lawsuit to be based in federal district court in California, North Carolina and Philadelphia.

January 20, 2024: Manufacturers of Ozempic and Mounjaro take differing positions in Lawsuit

The future of the Ozempic/Mounjaro litigation is still undecided. After an application by plaintiffs to organize the case in a Multi-District Litigation (MDL), the two largest defendants Novo Nordisk and Eli Lilly are split on their response to the application. Novo Nordisk, the manufacturer of Ozempic, has supported the application for consolidation but requests the case be heard in the Middle District of North Carolina or the Southern District of California. The Ozempic response was filed with the Panel on December 29, 2023. The different venues here are surprising. The middle of North Carolina is probably a play at a lower average income jury pool, as a way to limit exposure and perhaps a move towards more conservative jurors that would not be as likely to support drug use for weight loss. California on the other hand seems like a risky request. California verdicts can be some of the highest in the country. The defense must feel that the jury pool would think that it was common knowledge there were risks associated with the use of Ozempic.

Eli Lilly, the pharma giant and manufacturer of Mounjaro has asked the JPML to deny the plaintiffs’ motion for consolidation of the lawsuits. The Ozempic manufacturer probably thinks it will be too difficult and expensive to defend cases in virtually every federal court in America. The Mounjaro manufacturer is likely trying to distance themselves from Ozempic, which has been largely used and abused off label.

January 14, 2024: Application Made to organize Ozempic/Mounjaro lawsuits into a “class action” style MDL

A recent application by attorneys of those injured by the side effects of drugs like Ozempic and Mounjaro to the Judicial Panel for Multi-District Litigation (JPML), asks the panel of Judges to consider referring all Ozempic and similar lawsuits nationwide into a single federal district court. The benefits of consolidation into a Multi-District Litigation (MDL) include efficiency in the pre-trial discovery process, cost effectiveness for all parties, and fairness among all plaintiffs with similar injuries. An Ozempic MDL has similarities to an Ozempic Class Action Lawsuit, although the main benefit for plaintiffs is that an MDL allows for individualized settlements based upon the severity of each person’s case. The application includes the drugs Liraglutide, Dulaglutide, Semaglutide and Tirzepatide. Those drugs are marketed as Saxenda, Trulicity, Ozempic, Rybelsus, Wegovy and Mounjaro. King Law is currently investigating cases where individuals used these drugs and were further diagnosed with gastroparesis, stomach paralysis, gastrointestinal obstruction, and ileus.

January 7, 2024: Ozempic lawsuits increase in frequency following a recent study

Published in The Journal of the American Medical Association (JAMA), the study found Ozempic and other drugs with Glucagon-Like Peptide-1 Receptor Agonists are linked to pancreatitis, bowel obstruction and gastroparesis. The study by Mohit Sodhi, and colleagues, looked at a random sample of 16 million patients from 2006 to 2020. Ozempic lawsuits are popping up all over the country. The general claims are that Ozempic was not properly studied before its release, there were not proper warnings about the effects of Ozempic, and Ozempic is being used off label. Off-label use of medical devices and drugs like Ozempic is a common allegation in a lawsuit. Drugs are studied and approved for certain uses. In the case of Ozempic, the medication is approved for treatment of diabetes. We anticipate much of the Ozempic litigation will center around the marketing practices that encourage use for weight loss, instead of what the FDA said the drug could be safely used for.

August 2023 - November 2024

November 18, 2023: Ozempic Lawsuit Allegations Grow Internationally

In addition to a possible class action type lawsuit in the United States against the manufactures of the Diabetes drug Ozempic, a Canadian law firm has now filed a similar suit in British Columbia. The lawsuit alleges the same type of failure to warn of side effects such as Gastroparesis, Stomach Paralysis, Ileus, Gallbladder issues, and Gastric Intestinal Obstruction.

November 18, 2023: Ozempic Class Action MDL Lawsuit Could Come Summer 2024

A Class Action lawsuit could come as early as summer 2024 against the manufacturer of the popular drug Ozempic. The allegations are that the drug, which helps regulate type two diabetes and assist in weight loss, causes severe gastrointestinal problems. Those who have experienced these injuries claim that pharmaceutical companies Novo Nordisk and Eli Lilly failed to warn patients of the adverse side effects from Ozempic and its generic sister drug Semaglutide.

October 2023:

A research letter filed in the Journal of the American Medical Association alleges the risk of adverse gastrointestinal events associated with the use of GLP-1 agonists that are used not only to treat diabetes but also off-label for weight loss. The research concludes that there is an increased risk of pancreatitis, gastroparesis, and bowel obstruction with the use of the drugs.

August 2023:

The first lawsuit is filed against the makers of Ozempic and its sister drug Wegovy alleging a failure to adequately warn consumers about the potential risk of harm associated with using the drugs. The Ozempic lawsuit, filed against pharmaceutical giants Novo Nordisk and Eli Lilly, alleged that the drugs, both Glucagon-like peptide 1 (GLP-1) agonists, caused severe gastrointestinal issues.


On this page:

What Is Ozempic and How Does It Work?

What is Ozempic?

In December 2017, Novo Nordisk received approval from the U.S. Food and Drug Administration (FDA) for the use of their drug Ozempic as a weekly injectable to help treat adults with type 2 diabetes. The semaglutide is a weekly injectable that helps to lower blood sugar and reduce the risk of heart attack and stroke in people with type 2 diabetes and heart disease.

Though the drug was not initially approved for weight loss, it is increasingly prescribed off-label for this reason since weight loss is a common side effect. Wegovy, a higher dose injectable of the same drug, was approved by the FDA for weight management in 2021.

How does Ozempic work?

Ozempic and its sister drug Wegovy, are GLP-1 receptor agonists. GLP-1 receptor agonists work by slowing digestion through the release of a hormone that not only aids in insulin release but also blocks glucose production. It mimics a naturally occurring hormone that sends a signal to the brain when you are full, ultimately slowing digestion. It is intended for long-term use. Discontinuation of the drug can lead to the regaining of the weight that was lost.

Ozempic Side Effects and Health Risks

Studies show that the use of Ozempic may lead to an increased risk of gallbladder and biliary diseases. The risk may increase the longer that a patient remains on the drug and the higher the dose.

Ozempic side effects may include:

  • Acute kidney injury
  • Biliary diseases
  • Constipation
  • Diarrhea
  • Gallbladder inflammation
  • Gallstones
  • Gastroparesis
  • Hypoglycemia
  • Liver or kidney failure
  • Nausea
  • Pancreatitis
  • Suicidal thoughts
  • Thyroid cancer
  • Vision loss
  • Vomiting

In addition to these adverse health concerns, there is growing concern about a potential link between Ozempic and an increased risk of pancreatic cancer. The side effects of Ozempic do not necessarily go away after the drug is no longer being used. Some patients have reported continued gallbladder issues despite discontinuation of the use of the drug.

The risk of gallbladder problems is pronounced when the drug is used for long periods of time or at a higher dosage, which is typically the case when it is prescribed for weight loss. Individuals who have suffered gallbladder-related side effects after the use of Ozempic or Wegovy may be entitled to compensation through an Ozempic lawsuit due to the manufacturer’s failure to warn.

Ozempic Manufacturer: Novo Nordisk

Who manufactures Ozempic?

Ozempic and Wegovy are manufactured by the century-old Danish healthcare company Novo Nordisk. Since its inception in 1923, the company has focused on the treatment of diabetes through the extraction of insulin.

Prior to the development of Ozempic, the drug manufacturer sold Victoza, a once-daily GLP-1 injectable. The pharmaceutical company came under scrutiny for promoting Victoza for off-label uses, eventually agreeing to pay a $1.1 million whistleblower settlement. The company also agreed to pay $58 million to resolve lawsuits related to their failure to comply with an FDA-mandated risk program.

Novo Nordisk is currently facing litigation related to its failure to warn consumers about the potential risks associated with the use of Ozempic and Wegovy. New lawsuits allege that the manufacturer failed to put on the warning label the potential issues that can occur while using the drugs.

Eligibility Criteria for Filing an Ozempic Lawsuit

Individuals who have received a diagnosis for an adverse health condition after taking Ozempic, Rybelsus, or Wegovy GLP-1 receptor agonist treatments may be entitled to take legal action.

Eligibility criteria for filing an Ozempic lawsuit include:

  • Proof that you received Ozempic, Rybelsus, or Wegovy treatments;
  • A diagnosis of an adverse health condition such as Gastroparesis, Stomach Paralysis, Ileus, Bile Duct Cancer, Lou Gehrig’s Disease (ALS), Gallbladder Cancer, Sinus Cancer, or Gastric Intestinal Obstruction during treatment or within 30 days of using the drug. Our lawyers are also looking at the possibility of cases involving Pulmonary Embolism and Aspiration
  • An emergency room visit, hospitalization, or visit with Gastroenterologist, related to the condition.

It is critical to consult with an Ozempic lawyer to determine if you meet the criteria requirements and for state-specific statutes of limitations that may affect your case.

How to File an Ozempic Lawsuit

If you were diagnosed with Gastroparesis, Stomach Paralysis, Ileus, or Gastric Intestinal Obstruction during treatment or within 30 days of using the drug. related to the use of Ozempic or Wegovy, you might be entitled to compensation for your injuries. An Ozempic lawyer can help you understand your rights and determine whether you meet the criteria necessary to take legal action.

An Ozempic lawyer can help you by:

  • Offering a free case review to verify lawsuit eligibility;
  • Collecting evidence to support your claim, including medical records and witness testimonies;
  • Determining state-specific deadlines and statute of limitations;
  • Handling settlement negotiations; and
  • Setting the case for trial if a favorable settlement cannot be reached.

It is essential that you consult with a lawyer as early in the process as possible. During your meeting, you need to supply the attorney with all of your health information and supporting documentation related to your claim.


Ozempic Settlement Amounts

In Ozempic lawsuits, the primary determining factor in a potential settlement amount is the damages claimed and their calculated value. Since cases vary widely based on their individual damages, there is no standardized claim value. The estimated settlement value for cases involving gallbladder removal or wrongful death, however,  is approximately $400,000 to $700,000.

Damages in an Ozempic lawsuit may include compensation for losses related to:

  • Healthcare costs
  • Lost wages
  • Pain and suffering
  • Punitive damages

An attorney can help to maximize your compensation by filing a claim based on the full range of available damages. They can also provide guidance on what documentation is needed to demonstrate the value of your losses and negotiate to ensure a fair and full settlement is offered.

Contact an Ozempic Lawyer Today

At King Law, our Ozempic lawyers provide dedicated representation for individuals who have suffered adverse health conditions as a result of taking Ozempic, Wegovy, or other GLP-1 receptor agonists. We have years of experience advocating on behalf of those injured by dangerous drugs.

Our Ozempic attorneys will work tirelessly to ensure you receive the best possible outcome in your case. Contact our office today to schedule a free, no-obligation consultation. We proudly represent clients nationwide.

Frequently Asked Questions (FAQs)

Is there a class action lawsuit against Ozempic?
Yes, there is a class action lawsuit against Ozempic. On February 2, 2024, the Ozempic Lawsuit became official. It is called: MDL 3094 IN RE: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION. The lawsuit is organized in the Eastern District of Pennsylvania federal court. Hon. Gene E. K. Pratter is the Judge.
How much is the Ozempic lawsuit going to payout?
While there is no standardized settlement amount. It is anticipated that individuals with very serious injuries related to Ozempic may receive between $400,000 and $700,000. Lawsuit payouts, however, will vary.
What are the long-term side effects of Ozempic?
Studies show that prolonged use of Ozempic may increase the risk of gastrointestinal issues such as gastroparesis, stomach paralysis, and bowel blockage.
What is stomach paralysis from Ozempic?
Stomach paralysis or gastroparesis is a condition where the stomach fails to efficiently process food. Symptoms include vomiting, nausea, diarrhea, stomach cramps, and dehydration.
Can Ozempic cause permanent gastroparesis?
Legal action taken against Ozempic manufacturer Novo Nordisk alleges that the use of Ozempic may cause gastroparesis. It is possible that the condition remains permanent.
Can Ozempic cause intestinal blockage?
Allegations of intestinal blockage from the use of Ozempic are part of the current lawsuit.
Why is semaglutide being banned?
The use of semaglutide is being banned in some states due to its risk of potential harm and the reports of adverse effects by people who use the drug.
Is semaglutide the same as Ozempic?
Semaglutide is a generic name for Ozempic.
Who manufactures Ozempic?
Ozempic is manufactured by Novo Nordisk.
Is Rybelsus the same as Ozempic?
Rybelsus is a daily oral tablet that contains the same medication as the weekly injectable Ozempic.
Are Wegovy and Ozempic the same?
Wegovy is approved by the FDA for weight management. It contains a higher dose compared to Ozempic, which is used to treat Type 2 diabetes.